Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Revumenib for patients with acute leukemia: a new tool for differentiation therapy

1 Aug 2024

Abstract excerpt

Treatment of acute leukemia is gradually moving away from a "one-size-fits-all" approach, as scientific and clinical advances expand the arsenal of available targeted therapies. One of the recent additions is the group of menin inhibitors; oral, selective, small molecules that disrupt the interaction between the chromatin adapter menin, and an epigenetic regulator, the lysine methyltransferase 2A (KMT2A) complex....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Acute Myeloid Leukemia Research
Share to Histone Deacetylase Inhibitors Research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39086307
DOI: 10.3324/haematol.2022.282621

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 19 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Revumenib for patients with acute leukemia: a new tool for differentiation therapyPMID 39086307Read ↗

Menin inhibitors in the treatment of acute myeloid leukemiaSemantic proximity Read ↗

Combination Strategies with Menin Inhibitors for Acute LeukemiaSemantic proximity Read ↗

Menin Inhibitors: A New Era of Targeted Therapies in Acute Myeloid Leukemia.Semantic proximity Read ↗

The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemiaSemantic proximity Read ↗

Emerging drug profile: menin inhibitors in NPM1-mutated and KM2A-rearranged acute myeloid leukemia.Semantic proximity Read ↗

Menin inhibitors in KMT2A-rearranged and NPM1-mutated acute leukemia: A scoping review of safety and efficacySemantic proximity Read ↗

Targeting the Menin-KMT2A Axis in Acute Leukemia: From Epigenetic Dependency to Clinical Translation.Semantic proximity Read ↗

Small Molecule Menin Inhibitors: Novel Therapeutic Agents Targeting Acute Myeloid Leukemia with KMT2A Rearrangement or NPM1 MutationSemantic proximity Read ↗

Menin inhibitors for the treatment of acute myeloid leukemia: challenges and opportunities ahead.Semantic proximity Read ↗

Menin Inhibitors in Acute Myeloid Leukemia-What Does the Future Hold?Semantic proximity Read ↗

Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study.Semantic proximity Read ↗

The promise of menin inhibitors: from approval to triplet regimens.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.